Mutual, Hikma Settle Suit Over Unapproved Gout Drug

Law360, New York (October 20, 2010, 7:28 PM EDT) -- U.K.-based Hikma Pharmaceuticals PLC's U.S. unit has settled a lawsuit with Mutual Pharmaceutical Co. Inc. over the gout treatment Colcrys, agreeing to stop selling a competing version of the medication until it gets regulatory approval.

Judge Garrett E. Brown Jr. of the U.S. District Court for the District of New Jersey signed off on a stipulation of dismissal Wednesday between Hikma's West-Ward Pharmaceutical Corp. and Mutual, a subsidiary of URL Pharma Inc.

Hikma said it has stopped selling oral colchicine tablets until it receives approval for...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.